Skip to content

Low Molecular Weight Heparin on the Adenomyosis Patients'IVF-ET Outcome

To Study the Effect of Low Molecular Weight Heparin on the Adenomyosis Patients'Outcome of in Vitro Fertilization-embryo Transplantation

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04741295
Enrollment
70
Registered
2021-02-05
Start date
2020-02-01
Completion date
2022-01-31
Last updated
2021-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenomyosis, Assisted Reproductive Technology

Brief summary

In assisted reproductive technology, adenomyosis patients are characterized by lower clinical pregnancy rate, lower implantation rate and higher abortion rate. The purpose of this study is to explore whether low molecular weight heparin can reduce the abortion rate of adenomyosis patients in frozen thawed embryo transfer cycles.

Interventions

DRUGLow molecular weight heparin

Patients with adenomyosis were treated with low molecular weight heparin after frozen embryo transfer in addition to routine luteal support.

Sponsors

Nanjing University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 38 Years
Healthy volunteers
No

Inclusion criteria

1. The basal serum level of FSH was less than 10 IU / L 2. Diagnosed with adenomyosis by ultrasound 3. The first frozen thawed embryo transfer cycle, by hormone replacement protocol 4. Transfer at least one high quality frozen embryo; 5. Patients agreed to use low molecular weight heparin after FET, and they were able to sign informed consent in person.

Exclusion criteria

1. With abnormal karyotype; 2. Accompanied with other uterine diseases: intrauterine adhesion, intramural myoma, moderate to severe endometriosis, congenital uterine malformation, endometrial tuberculosis, thin endometrium \< 8mm on the day of transformation, etc; 3. PCOS, RIF patients; 4. There are indications of conventional anticoagulation or antiplatelet therapy, such as antiphospholipid syndrome, autoimmune diseases, coagulation dysfunction, etc; 5. There were contraindications to hormone replacement therapy and low molecular weight heparin; 6. Participating in other clinical studies; 7. Unable to follow-up

Design outcomes

Primary

MeasureTime frame
Early spontaneous abortion rateWithin three months after frozen embryo transfer

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026